Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Feb 14, 2024

BUY
$0.3 - $2.74 $6,358 - $58,074
21,195 New
21,195 $10,000
Q2 2022

Jul 26, 2022

BUY
$0.3 - $2.74 $6,358 - $58,074
21,195 New
21,195 $10,000
Q4 2020

Feb 10, 2021

SELL
$3.33 - $7.18 $57,345 - $123,646
-17,221 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$2.28 - $6.6 $177,876 - $514,905
-78,016 Reduced 81.92%
17,221 $64,000
Q4 2019

Feb 11, 2020

SELL
$3.34 - $5.51 $33,987 - $56,069
-10,176 Reduced 9.65%
95,237 $447,000
Q1 2019

May 10, 2019

SELL
$7.71 - $11.24 $1.67 Million - $2.44 Million
-217,149 Reduced 67.32%
105,413 $0
Q4 2018

Jan 31, 2019

SELL
$7.3 - $18.3 $988,376 - $2.48 Million
-135,394 Reduced 29.56%
322,562 $2.35 Million
Q3 2018

Nov 14, 2018

BUY
$9.77 - $17.15 $4.3 Million - $7.55 Million
440,499 Added 2523.34%
457,956 $0
Q2 2018

Aug 03, 2018

SELL
$5.43 - $9.83 $1.26 Million - $2.28 Million
-232,074 Reduced 93.0%
17,457 $0
Q1 2018

May 09, 2018

BUY
$5.79 - $8.86 $987,316 - $1.51 Million
170,521 Added 215.82%
249,531 $0
Q4 2017

Feb 07, 2018

SELL
$5.88 - $9.09 $3.31 Million - $5.12 Million
-563,276 Reduced 87.7%
79,010 $0
Q3 2017

Nov 13, 2017

BUY
$7.55 - $9.43 $4.85 Million - $6.06 Million
642,286
642,286 $0

About Endo International plc


  • Ticker ENDP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 235,143,008
  • Market Cap $68.8M
  • Description
  • Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocio...
More about ENDP
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.